Curing cervical cancer or preventing it: A case of opportunity cost in the long run?

Vaccine

Volumn 32, Issue 51, 2014, Pages 6867-6869

  van de Vooren, Katelijne ^a   Curto, Alessandro ^a   Garattini, Livio ^a  

^a CESAV   (Italy)

Author keywords

Bevacizumab; Cervical cancer; HPV vaccines; Opportunity cost

Indexed keywords

WART VIRUS VACCINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY;

BUDGET; BUDGET IMPACT ANALYSIS; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; EARLY INTERVENTION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; ADOLESCENT; ECONOMICS; FEMALE; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84924068408     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.014     Document Type: Note

References (16)

1. HPV Information Centre: Publications and technical reports. [accessed 10.06.14]. http://www.hpvcentre.net/hpvpublications.php.
2. Vici P., Mariani L., Pizzuti L., Sergi D., Di Lauro L., Vizza E., et al. Emerging biological treatments for uterine cervical carcinoma. J Cancer 2014, 5(2):86-97.
3. Tewari K.S., Sill M.W., Long H.J., Penson R.T., Huang H., Ramondetta L.M., et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014, 370(February (8)):734-743.
4. FDA News Release August 14, 2014. FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer. [accessed 26.09.14]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm410121.htm.
5. NHS England News. New cervical cancer drug added to Cancer Drugs Fund, 6 March 2014. [accessed 10.06.14]. http://www.england.nhs.uk/2014/03/06/new-cervical-cancer-drug/.
6. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccines 2011, 7(2):161-169.
7. Stanley M., Lowy D.R., Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006, 24(Suppl. 3). S3/106-113.
8. European Centre for Disease Prevention and Control Introduction of HPV vaccines in EU countries - an update 2012, ECDC, Stockholm.
9. Koleva D., De Compadri P., Padula A., Garattini L. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med 2011, 6(2):163-174.
10. Garattini L., Van de Vooren K., Freemantle N. Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines. J R Soc Med 2014, 107(1):4-5.
11. Palmer S., Raftery J. Opportunity cost. BMJ 1999, 318(June (7197)):1551-1552.
12. Garattini L., van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ 2011, 12(December (6)):499-502.
13. Gazzetta Ufficiale della Repubblica Italiana. Determina AIFA 26 novembre 2013. [accessed 10.06.14]. http://www.gazzettaufficiale.it/eli/id/2013/12/23/13A10289/sg.
14. Odone A., Gallus S., Lugo A., Zuccaro P., Colombo P., Bosetti C., et al. Weight perception among Italian adults, 2006-2010. Eur J Cancer Prev 2014, 23(2):141-146.
15. AIFA. L'uso dei Farmaci in Italia. Rapporto Nazionale, anno 2012. [accessed 10.06.14]. http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdf.
16. WHO Evidence based recommendations on human papilloma virus (HPV) vaccines schedules March 11, 2014, http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence:based_recommendationsWHO_with_Appendices2_3.pdf [accessed 10.06.14].